Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Blood

Volumn 123, Issue 7, 2014, Pages 985-991

  Ludwig, Heinz ^a   Kasparu, Hedwig ^b   Leitgeb, Clemens ^a   Rauch, Elisabeth ^a   Linkesch, Werner ^c   Zojer, Niklas ^a   Greil, Richard ^d   Seebacher, Adelheid ^e   Pour, Ludek ^f   Weimßann, Adalbert ^a   Adam, Zdeneǩ ^f  

^a WILHELMINEN HOSPITAL   (Austria)

^b ELISABETHINEN HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d University Hospital Salzburg   (Austria)

^e HANUSCH HOSPITAL   (Austria)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; DEXAMETHASONE; LACTATE DEHYDROGENASE; LENALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; FATIGUE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPHIL; OVERALL SURVIVAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 84897849395     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-521468     Document Type: Article

References (30)

1. Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013;160(5): 649-659.
2. Kalaycio M. Bendamustine: a new look at an old drug. Cancer. 2009;115(3):473-479.
3. Roué G, López-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res. 2008;14(21):6907-6915.
4. Balfour JA, Goa KL. Bendamustine. Drugs. 2001; 61(5):631-638, discussion 639-640.
5. Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol. 2011;48(Suppl 1): S12-S23.
6. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14(1):309-317. (Pubitemid 351378007)
7. Cives M, Ciavarella S, Rizzo FM, De Matteo M, Dammacco F, Silvestris F. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013;25(5):1108-1117.
8. Cai B, Wang S, Huang J, Lee CK, Gao C, Liu B. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res. 2013; 5(1):36-46.
9. Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132(4):205-212. (Pubitemid 43144255)
10. Durie BGM, Harousseau JL, Miguel JS, et al International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
11. Bladé J, Samson D, Reece D, et al Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123. (Pubitemid 28435189)
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(24):457-481.
13. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A. 1972;135:185-206.
14. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-202.
15. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119(20): 4608-4613.
16. Pönisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol. 2013;162(2):202-209.
17. Hrusovsky I, Heidtmann HH. Combination therapy of bortezomib with bendamustine in elderly patients with advanced multiple myeloma [abstract]. Blood. 2007;110(11). Abstract 4851.
18. Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2013;139(3): 499-508.
19. Rodon P, Hulin C, Pegourie B, et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly MM progressive after 1st line therapy (IFM- 2009-01 trial): predictive factors of favourable outcome [abstract]. Haematologica. 2013;98(Suppl 1):100. Abstract P231.
20. Offidani M, Corvatta L, Caraffa P, et al. Bendamustine, bortezomib and dexamethasone (BVD) combination for the treatment of relapsed/ refractory multiple myeloma: An interim analysis of a phase II study [abstract]. Haematologica. 2012;97(Suppl 1):353. Abstract 858.
21. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica. 2005; 90(9):1287-1288. (Pubitemid 41375295)
22. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160(3):321-330.
23. Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol. 2012; 156(4):552-555, author reply 555.
24. Pönisch W, Rozanski M, Goldschmidt H, et al East German Study Group of Haematology and Oncology (OSHO). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol. 2008;143(2):191-200.
25. Preiss R, Teichert J, Seidel A, et al. Pharmacokinetics and toxicity profile of bendamustine in myeloma patients with end-stage renal disease [abstract]. Hematology J. 2003;4(Suppl 1). Abstract 394.
26. Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? Acta Haematol. 2011;126(3):163-168.
27. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011;155(5):632-634.
28. Richardson PG, Sonneveld P, Schuster MW, et al Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-2498. (Pubitemid 41007864)
29. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25): 3892-3901. (Pubitemid 47477266)
30. Zhang S, Wang X, Chen L, et al. Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cells [abstract]. Blood. 2008;112(11). Abstract 5171.